Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BT1718 in advanced solid tumours
NCT03486730Phase 2Completed
- Sponsor
- Cancer Research UK
- Start
- Jan 2018
- Primary completion
- Nov 2023
- Modality
- Cyclic Peptides, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of BT1718 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC) and esophageal cancer (2 arms), sponsored by Cancer Research UK. Primary endpoints: Maximum Tolerated Dose and Adverse Events. Started Jan 2018; status: completed.
02
Drugs
BT1718
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)esophageal cancer
Beyond the preview
Go deeper on NCT03486730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03486730.